NCT04469556View on ClinicalTrials.gov

Pancreatic Adenocarcinoma Signature Stratification for Treatment

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

January 31, 2025

Study Completion Date

September 30, 2026

Conditions
Pancreatic Cancer MetastaticPancreatic Ductal AdenocarcinomaAdvanced Pancreatic Cancer
Interventions
DRUG

Folfirinox

Chemotherapy

DRUG

Gemcitabine/nab-paclitaxel

Chemotherapy

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

11042

Northwell Health, New Hyde Park

21231

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

02215

Dana Farber Cancer Institute, Boston

V5Z 1L8

BC Cancer Agency Vancouver, Vancouver

M5G 2N9

Princess Margaret Cancer Centre, Toronto

Sponsors
All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

collaborator

Cold Spring Harbor Laboratory

OTHER

collaborator

Ontario Institute for Cancer Research

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Stand Up To Cancer

OTHER

lead

University Health Network, Toronto

OTHER